SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Laurent Azoulay, Samy Suissa, Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies, Diabetes Care, 2017, 40, 5, 706

    CrossRef

  2. 2
    Manel Pladevall, Nuria Riera-Guardia, Andrea V Margulis, Cristina Varas-Lorenzo, Brian Calingaert, Susana Perez-Gutthann, Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies, BMC Cardiovascular Disorders, 2016, 16, 1

    CrossRef

  3. 3
    D. T. Eurich, D. L. Weir, S. H. Simpson, A. Senthilselvan, F. A. McAlister, Risk of new-onset heart failure in patients using sitagliptin: a population-based cohort study, Diabetic Medicine, 2016, 33, 5
  4. 4
    Y.-C. Chang, L.-M. Chuang, J.-W. Lin, S.-T. Chen, M.-S. Lai, C.-H. Chang, Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study, Diabetic Medicine, 2015, 32, 11
  5. 5
    Jihan Youssef, Mostafa Badr, Peroxisome Proliferator-Activated Receptors Features, Functions, and Future, Nuclear Receptor Research, 2015, 2,

    CrossRef

  6. 6
    Elisabetta Patorno, Amanda R. Patrick, Elizabeth M. Garry, Sebastian Schneeweiss, Victoria G. Gillet, Dorothee B. Bartels, Elvira Masso-Gonzalez, John D. Seeger, Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations, Diabetologia, 2014, 57, 11, 2237

    CrossRef

  7. 7
    A. S. Abdelmoneim, D. T. Eurich, J. M. Gamble, J. A. Johnson, J. M. Seubert, W. Qiu, S. H. Simpson, Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case–control study, Diabetes, Obesity and Metabolism, 2014, 16, 1
  8. 8
    Yanping Li, Yang Hu, Sylvia H. Ley, Swapnil Rajpathak, Frank B. Hu, Sulfonylurea Use and Incident Cardiovascular Disease Among Patients With Type 2 Diabetes: Prospective Cohort Study Among Women, Diabetes Care, 2014, 37, 11, 3106

    CrossRef

  9. 9
    O. J. Phung, E. Schwartzman, R. W. Allen, S. S. Engel, S. N. Rajpathak, Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis, Diabetic Medicine, 2013, 30, 10
  10. 10
    Philip Home, Cardiovascular Disease and Oral Agent Glucose-Lowering Therapies in the Management of Type 2 Diabetes, Diabetes Technology & Therapeutics, 2012, 14, S1, S-33

    CrossRef

  11. You have free access to this content11
    Roy Eldor, Itamar Raz, Diabetes therapy-focus on Asia: second-line therapy debate: insulin/secretagogues, Diabetes/Metabolism Research and Reviews, 2012, 28,
  12. 12
    Patricia Mona Eng, T. Christopher Mast, Jeanne Loughlin, C. Robin Clifford, Judy Wong, John D. Seeger, Incidence of Intussusception Among Infants in a Large Commercially Insured Population in the United States, The Pediatric Infectious Disease Journal, 2012, 31, 3, 287

    CrossRef

  13. 13
    Jacqueline Kung, Robert R Henry, Thiazolidinedione safety, Expert Opinion on Drug Safety, 2012, 11, 4, 565

    CrossRef

  14. 14
    Henriette Thisted Horsdal, Flemming Søndergaard, Søren Paaske Johnsen, Jørgen Rungby, Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case–control study, Pharmacoepidemiology and Drug Safety, 2011, 20, 4
  15. 15
    G. Nicholson, G.M. Hall, Diabetes mellitus: new drugs for a new epidemic, British Journal of Anaesthesia, 2011, 107, 1, 65

    CrossRef

  16. 16
    Somsuvra B. Ghatak, Prakash S. Dhamecha, Shraddha V. Bhadada, Shital J. Panchal, Investigation of the potential effects of metformin on atherothrombotic risk factors in hyperlipidemic rats, European Journal of Pharmacology, 2011, 659, 2-3, 213

    CrossRef

  17. 17
    Arlene M. Gallagher, Liam Smeeth, Suzie Seabroke, Hubert G. M. Leufkens, Tjeerd P. van Staa, German Malaga, Risk of Death and Cardiovascular Outcomes with Thiazolidinediones: A Study with the General Practice Research Database and Secondary Care Data, PLoS ONE, 2011, 6, 12, e28157

    CrossRef

  18. 18
    P. Home, Safety of PPAR Agonists, Diabetes Care, 2011, 34, Supplement_2, S215

    CrossRef

  19. 19
    Sanjay Kaul, Ann F. Bolger, David Herrington, Robert P. Giugliano, Robert H. Eckel, Thiazolidinedione Drugs and Cardiovascular Risks, Journal of the American College of Cardiology, 2010, 55, 17, 1885

    CrossRef

  20. 20
    Mark F. McCarty, Jorge Barroso-Aranda, Francisco Contreras, Activation of AMP-activated kinase as a strategy for managing autosomal dominant polycystic kidney disease, Medical Hypotheses, 2009, 73, 6, 1008

    CrossRef

  21. 21
    David D. Dore, Amal N. Trivedi, Vincent Mor, Kate L. Lapane, Association Between Extent of Thiazolidinedione Exposure and Risk of Acute Myocardial Infarction, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2009, 29, 7
  22. 22
    Kasia Lipska, Silvio E. Inzucchi, Cardiovascular risk-benefit ratio of thiazolidinediones, Current Cardiovascular Risk Reports, 2009, 3, 1, 42

    CrossRef

  23. 23
    George M. Hall, Grainne Nicholson, Current Therapeutic Drugs for Type 2 Diabetes, Still Useful After 50 Years?, Anesthesia & Analgesia, 2009, 108, 6, 1727

    CrossRef

  24. 24
    Gregory A Grabowski, Katherine Kacena, J Alexander Cole, Carla E M Hollak, Lin Zhang, John Yee, Pramod K Mistry, Ari Zimran, Joel Charrow, Stephan vom Dahl, Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1, Genetics in Medicine, 2009, 11, 2, 92

    CrossRef

  25. 25
    Giuseppe Derosa, Sibilla Anna Teresa Salvadeo, Glimepiride-pioglitazone Hydrochloride in the Treatment of Type 2 Diabetes, Clinical Medicine. Therapeutics, 2009, 1, CMT.S2016

    CrossRef

  26. 26
    M. Fisher, Improving cardiovascular risk – applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes, International Journal of Clinical Practice, 2009, 63, 9
  27. 27
    Zeina A. Habib, Leonidas Tzogias, Suzanne L. Havstad, Karen Wells, George Divine, David E. Lanfear, Jeffrey Tang, Richard Krajenta, Manel Pladevall, L. Keoki Williams, Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis, Pharmacoepidemiology and Drug Safety, 2009, 18, 6
  28. 28
    Karen M. Stockl, Lisa Le, Shaoang Zhang, Ann S.M. Harada, Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications, Pharmacoepidemiology and Drug Safety, 2009, 18, 2
  29. 29
    Philip D Home, Stuart J Pocock, Henning Beck-Nielsen, Paula S Curtis, Ramon Gomis, Markolf Hanefeld, Nigel P Jones, Michel Komajda, John JV McMurray, Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial, The Lancet, 2009, 373, 9681, 2125

    CrossRef

  30. 30
    Alain Vanasse, André C. Carpentier, Josiane Courteau, Shabnam Asghari, Stroke and cardiovascular morbidity and mortality associated with rosiglitazone use in elderly diabetic patients, Diabetes and Vascular Disease Research, 2009, 6, 2, 87

    CrossRef

  31. 31
    Kevin M. Pantalone, Michael W. Kattan, Changhong Yu, Brian J. Wells, Susana Arrigain, Anil Jain, Ashish Atreja, Robert S. Zimmerman, The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis, Acta Diabetologica, 2009, 46, 2, 145

    CrossRef

  32. 32
    M. Hanefeld, The role of pioglitazone in modifying the atherogenic lipoprotein profile, Diabetes, Obesity and Metabolism, 2009, 11, 8
  33. 33
    Najat Ziyadeh, Andrew T. McAfee, Carol Koro, Joan Landon, K. Arnold Chan, The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: A retrospective cohort study using a US health insurance database, Clinical Therapeutics, 2009, 31, 11, 2665

    CrossRef

  34. 34
    Fei-Yuan Hsiao, Weng-Foung Huang, Yu-Wen Wen, Pei-Fen Chen, Ken N. Kuo, Yi-Wen Tsai, Thiazolidinediones and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus, Drug Safety, 2009, 32, 8, 675

    CrossRef

  35. 35
    S Ward Casscells, Elder Granger, Joe Swedorske, Rhonda Goldhammer, Megan Shaheen, Joe Dorris, Allison Hong, Michael Wiktor, A Comparison of Select Cardiovascular Outcomes by Antidiabetic Prescription Drug Classes Used to Treat Type 2 Diabetes Among Military Health System Beneficiaries, Fiscal Year 2003-2006, American Journal of Therapeutics, 2008, 15, 3, 198

    CrossRef

  36. 36
    Alexander Cobitz, Andrew Zambanini, Margaret Sowell, Mark Heise, Bonnie Louridas, Stephen McMorn, Marc Semigran, Gary Koch, A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14 237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone, Pharmacoepidemiology and Drug Safety, 2008, 17, 8
  37. 37
    Carol E. Koro, Qinggong Fu, Monika Stender, An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients, Pharmacoepidemiology and Drug Safety, 2008, 17, 10
  38. 38
    Allison B. Goldfine, Assessing the Cardiovascular Safety of Diabetes Therapies, New England Journal of Medicine, 2008, 359, 11, 1092

    CrossRef

  39. 39
    David J. Margolis, Ole Hoffstad, Brian L. Strom, Association between serious ischemic cardiac outcomes and medications used to treat diabetes, Pharmacoepidemiology and Drug Safety, 2008, 17, 8
  40. 40
    Gerald A. Faich, Annette Stemhagen, Cardiac safety of diabetes therapies and postmarketing requirements, Pharmacoepidemiology and Drug Safety, 2008, 17, 8
  41. 41
    Javier C. Waksman, Cardiovascular risk of rosiglitazone: another perspective, Journal of Pharmacy and Pharmacology, 2008, 60, 12
  42. 42
    Alexander M. Walker, Carol E. Koro, Joan Landon, Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000–2007, Pharmacoepidemiology and Drug Safety, 2008, 17, 8
  43. 43
    Anand Rohatgi, Darren K. McGuire, Effects of the Thiazolidinedione Medications on Micro- and Macrovascular Complications in Patients with Diabetes—Update 2008, Cardiovascular Drugs and Therapy, 2008, 22, 3, 233

    CrossRef

  44. 44
    Sanjay Kaul, George A Diamond, Have the risks of rosiglitazone been exaggerated?, Future Cardiology, 2008, 4, 1, 9

    CrossRef

  45. 45
    Clifford J. Bailey, Metformin: Effects on Micro and Macrovascular Complications in Type 2 Diabetes, Cardiovascular Drugs and Therapy, 2008, 22, 3, 215

    CrossRef

  46. 46
    M.C.E. Bragt, H.E. Popeijus, Peroxisome proliferator-activated receptors and the metabolic syndrome, Physiology & Behavior, 2008, 94, 2, 187

    CrossRef

  47. 47
    Mylène Perreault, David V. Erbe, James F. Tobin, PPAR Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities, PPAR Research, 2008, 2008, 1

    CrossRef

  48. 48
    Sanjay Kaul, George A. Diamond, Rosiglitazone and cardiovascular risk, Current Atherosclerosis Reports, 2008, 10, 5, 398

    CrossRef

  49. 49
    James D. Lewis, Gary R. Lichtenstein, Julius J. Deren, Bruce E. Sands, Stephen B. Hanauer, Jeffrey A. Katz, Bret Lashner, Daniel H. Present, Shaokun Chuai, Jonas H. Ellenberg, Lisa Nessel, Gary D. Wu, Rosiglitazone for Active Ulcerative Colitis: A Randomized Placebo-Controlled Trial, Gastroenterology, 2008, 134, 3, 688

    CrossRef

  50. 50
    Jennifer G. Robinson, Should We Use PPAR Agonists to Reduce Cardiovascular Risk?, PPAR Research, 2008, 2008, 1

    CrossRef

  51. 51
    Ramzi A Ajjan, Peter J Grant, The cardiovascular safety of rosiglitazone, Expert Opinion on Drug Safety, 2008, 7, 4, 367

    CrossRef

  52. 52
    Allison B Goldfine, The rough road for rosiglitazone, Current Opinion in Endocrinology, Diabetes and Obesity, 2008, 15, 2, 113

    CrossRef

  53. 53
    Manel Mata Cases, Tratamiento combinado de la diabetes mellitus tipo 2, FMC - Formación Médica Continuada en Atención Primaria, 2008, 15, 3, 159

    CrossRef

  54. 54
    H. T. Horsdal, S. P. Johnsen, F. Søndergaard, J. Rungby, Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study, Diabetologia, 2008, 51, 4, 567

    CrossRef

  55. 55
    Nasser Mikhail, Why Should We Avoid the Use of Rosiglitazone?, Southern Medical Journal, 2008, 101, 3, 329

    CrossRef

  56. 56
    Charles M. Gerrits, Mondira Bhattacharya, Shivaji Manthena, Robert Baran, Alfonso Perez, Stuart Kupfer, A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes, Pharmacoepidemiology and Drug Safety, 2007, 16, 10
  57. 57
    Current awareness: Pharmacoepidemiology and drug safety, Pharmacoepidemiology and Drug Safety, 2007, 16, 11
  58. 58
    Brian L. Strom, James D. Lewis, In clarification, Pharmacoepidemiology and Drug Safety, 2007, 16, 10
  59. 59
    Catherine B. Johannes, John D. Seeger, Carol E. Koro, Jennifer A. Cutone, Sherry G. Quinn, Response to a comment on ‘the risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy’, Pharmacoepidemiology and Drug Safety, 2007, 16, 10
  60. 60
    Emma D Deeks, Susan J Keam, Rosiglitazone, Drugs, 2007, 67, 18, 2747

    CrossRef

  61. 61
    Alexander M. Walker, Andrew T. McAfee, Carol Koro, Studies of diabetes, thiazolidinediones, and coronary heart disease, Pharmacoepidemiology and Drug Safety, 2007, 16, 12
  62. 62
    Stephen J. W. Evans, Dorothea Nitsch, Statistics: Analysis and Presentation of Safety Data,